JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Preston, K. L.
Right arrow Articles by Liebson, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Preston, K. L.
Right arrow Articles by Liebson, I. A.

Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts

KL Preston, GE Bigelow and IA Liebson

The subjective, physiological and behavioral effects of morphine, pentazocine and ciramadol, an opioid agonist/antagonist, were studied in adult male nondependent opioid abusers living on a clinical research ward. Fifteen subjects were assigned randomly to one of three groups. Each group received, by i.m. injection, placebo and three doses of one active drug, twice in randomized block order under double-blind conditions in 4.5-hr experimental sessions. Physiological measures did not differentiate between the three drugs. All three drugs decreased respiratory rate and pupil diameter and increased blood pressure. However, morphine, ciramadol and pentazocine produced different profiles on the subjective effect measures. All three drugs increased "liking," "good effects," "any effects" and "high" subjective effect scales. Pentazocine increased subjective "bad effects" scale scores and scales measuring dysphoria and sedation. Observers reported significant behavioral changes after administration of morphine and pentazocine, but not after ciramadol. Overall, the effects of morphine (7.5, 15 and 30 mg) and pentazocine (22.5, 45 and 90 mg) were dose-related. Although pentazocine produced increases in scales that indicated negative subjective effects, it also produced significant changes in most self- report measures that were increased by morphine, including liking and good effects scales. The effects of ciramadol were not dose-related, with all three doses (30, 60 and 120 mg) producing effects approximately equivalent to morphine 15 mg. Thus, ciramadol exhibited a ceiling effect typical of the opioid agonist/antagonist.

Volume 240, Issue 3, pp. 900-910, 03/01/1987
Copyright © 1987 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 NEJMHome page
M. C. Rowbotham, L. Twilling, P. S. Davies, L. Reisner, K. Taylor, and D. Mohr
Oral Opioid Therapy for Chronic Peripheral and Central Neuropathic Pain
N. Engl. J. Med., March 27, 2003; 348(13): 1223 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. E. Jones, G. E. Bigelow, and K. L. Preston
Assessment of Opioid Partial Agonist Activity with a Three-Choice Hydromorphone Dose-Discrimination Procedure
J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1350 - 1361.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. P. Zacny, J. L. Hill, M. L. Black, and P. Sadeghi
Comparing the Subjective, Psychomotor and Physiological Effects of Intravenous Pentazocine and Morphine in Normal Volunteers
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1197 - 1207.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1987 by the American Society for Pharmacology and Experimental Therapeutics.